98 related articles for article (PubMed ID: 35173526)
1. SOX8 Affects Tumoral SPARC Expression by Regulating EZH2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC.
Yuan S; Xu J; Zhou B; Zhou Y; Lang M; Cao J; Liu Z; Yang S; Gao S; Hao J
Int J Biol Sci; 2022; 18(3):911-922. PubMed ID: 35173526
[TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
[TBL] [Abstract][Full Text] [Related]
3. EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma.
Li CH; Xiao Z; Tong JH; To KF; Fang X; Cheng AS; Chen Y
Int J Cancer; 2017 Jan; 140(1):120-129. PubMed ID: 27594424
[TBL] [Abstract][Full Text] [Related]
4. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
Neesse A; Frese KK; Chan DS; Bapiro TE; Howat WJ; Richards FM; Ellenrieder V; Jodrell DI; Tuveson DA
Gut; 2014 Jun; 63(6):974-83. PubMed ID: 24067278
[TBL] [Abstract][Full Text] [Related]
5. SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer.
Vaz J; Ansari D; Sasor A; Andersson R
Pancreas; 2015 Oct; 44(7):1024-35. PubMed ID: 26335014
[TBL] [Abstract][Full Text] [Related]
6. Stromal expression of SPARC in pancreatic adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Cros J; Faivre S; Hammel P; Raymond E
Cancer Metastasis Rev; 2013 Dec; 32(3-4):585-602. PubMed ID: 23690170
[TBL] [Abstract][Full Text] [Related]
7. Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma.
Han T; Zhuo M; Yuan C; Xiao X; Cui J; Qin G; Wang L; Jiao F
Cancer Biol Med; 2020 Nov; 17(4):953-969. PubMed ID: 33299646
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of long noncoding RNA SNHG14 suppresses cell proliferation and invasion by regulating EZH2 in pancreatic ductal adenocarcinoma (PDAC).
Xie F; Huang Q; Wang C; Chen S; Liu C; Lin X; Lv X; Wang C
Cancer Biomark; 2020; 27(3):357-364. PubMed ID: 31929143
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.
Duan J; Hao Y; Wan R; Yu S; Bai H; An T; Zhao J; Wang Z; Zhuo M; Wang J
Thorac Cancer; 2017 May; 8(3):138-146. PubMed ID: 28304139
[TBL] [Abstract][Full Text] [Related]
10. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression.
Chen G; Tian X; Liu Z; Zhou S; Schmidt B; Henne-Bruns D; Bachem M; Kornmann M
Br J Cancer; 2010 Jan; 102(1):188-95. PubMed ID: 19920824
[TBL] [Abstract][Full Text] [Related]
12. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK
J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503
[TBL] [Abstract][Full Text] [Related]
13. Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer.
Patil S; Forster T; Reutlinger K; Kopp W; Versemann L; Spitalieri J; Gaedcke J; Ströbel P; Singh SK; Ellenrieder V; Neesse A; Hessmann E
Cells; 2021 Dec; 10(12):. PubMed ID: 34943970
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients.
Singh N; Rashid S; Rashid S; Dash NR; Gupta S; Saraya A
J Cancer Res Clin Oncol; 2020 Apr; 146(4):897-907. PubMed ID: 32146565
[TBL] [Abstract][Full Text] [Related]
15. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials.
Ormanns S; Haas M; Baechmann S; Altendorf-Hofmann A; Remold A; Quietzsch D; Clemens MR; Bentz M; Geissler M; Lambertz H; Kruger S; Kirchner T; Heinemann V; Boeck S
Br J Cancer; 2016 Dec; 115(12):1520-1529. PubMed ID: 27802454
[TBL] [Abstract][Full Text] [Related]
16. Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity.
Chen NM; Neesse A; Dyck ML; Steuber B; Koenig AO; Lubeseder-Martellato C; Winter T; Forster T; Bohnenberger H; Kitz J; Reuter-Jessen K; Griesmann H; Gaedcke J; Grade M; Zhang JS; Tsai WC; Siveke J; Schildhaus HU; Ströbel P; Johnsen SA; Ellenrieder V; Hessmann E
Gastroenterology; 2017 May; 152(6):1507-1520.e15. PubMed ID: 28188746
[TBL] [Abstract][Full Text] [Related]
17. Fibronectin acts as a molecular switch to determine SPARC function in pancreatic cancer.
Munasinghe A; Malik K; Mohamedi F; Moaraf S; Kocher H; Jones L; Hill NJ
Cancer Lett; 2020 May; 477():88-96. PubMed ID: 32113990
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.
Gonzalez-Villasana V; Rodriguez-Aguayo C; Arumugam T; Cruz-Monserrate Z; Fuentes-Mattei E; Deng D; Hwang RF; Wang H; Ivan C; Garza RJ; Cohen E; Gao H; Armaiz-Pena GN; Del C Monroig-Bosque P; Philip B; Rashed MH; Aslan B; Erdogan MA; Gutierrez-Puente Y; Ozpolat B; Reuben JM; Sood AK; Logsdon C; Lopez-Berestein G
Mol Cancer Ther; 2014 Nov; 13(11):2583-94. PubMed ID: 25193509
[TBL] [Abstract][Full Text] [Related]
19. SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas.
Pascual-Pasto G; Castillo-Ecija H; Unceta N; Aschero R; Resa-Pares C; Gómez-Caballero A; Vila-Ubach M; Muñoz-Aznar O; Suñol M; Burgueño V; Gomez-Gonzalez S; Sosnik A; Ibarra M; Schaiquevich P; de Álava E; Tirado OM; Mora J; Carcaboso AM
J Control Release; 2022 Feb; 342():81-92. PubMed ID: 34974029
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines.
Braun LM; Lagies S; Guenzle J; Fichtner-Feigl S; Wittel UA; Kammerer B
Cells; 2020 May; 9(5):. PubMed ID: 32438599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]